OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ocular Therapeutix Inc (OCUL) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has potential due to positive analyst ratings and hedge fund interest, the technical indicators are bearish, financial performance is weak, and the ongoing lawsuit introduces significant uncertainty. A hold is recommended until more clarity emerges on the legal case and financial recovery.
The technical indicators are bearish. The MACD is below zero and negatively contracting, RSI is neutral at 28.998, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 7.916, with resistance at 8.875.
Analysts have raised price targets significantly, with targets ranging from $27 to $34, citing strong Phase 3 trial data and potential approval for Axpaxli.
Hedge fund buying has increased by 2312.47% over the last quarter, indicating institutional confidence.
The ongoing lawsuit with EyePoint could damage investor confidence and market performance.
Insiders are selling, with a 186.05% increase in selling activity over the last month.
Financial performance in Q4 2025 was weak, with revenue dropping 22.43% YoY and gross margin declining by 5.20%.
In Q4 2025, revenue dropped to $13.25M (-22.43% YoY), net income improved to -$64.65M (+33.62% YoY), and EPS remained flat at -0.29. Gross margin declined to 87.97% (-5.20% YoY), reflecting operational challenges.
Analysts are bullish on OCUL, with multiple Buy ratings and raised price targets (e.g., $27-$34). They highlight strong Phase 3 trial data and potential approval for Axpaxli, which addresses a significant unmet need in the $14B wet AMD market.
